You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
10 June 2024
Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
8 March 2024
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
28 February 2024
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD™ 2024 Conference
25 October 2023
Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations (news with additional features)